Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner

Acta Pharmacologica Sinica

Volumn 29, Issue 8, 2008, Pages 951-964

  Huang, Jian ^a,b,c   Yang, Min ^a,b,c   Liu, Hui ^a,b,c   Jin, Jie ^a,b,c  

^a First Affiliated Hospital   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Apoptosis; Cell differentiation agent 2(CDA 2); Human urine extract; Myelodysplastic syndrome; Phosphoinositide 3 kinase Akt; Xenograft

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CELL CYCLE PROTEIN; CELL DIFFERENTIATION AGENT 2; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REFRACTORY ANEMIA; SIGNAL TRANSDUCTION; SURVIVAL; URINE; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; MICE, SCID; MITOCHONDRIAL MEMBRANES; MYELODYSPLASTIC SYNDROMES; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; URINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49249094942     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00826.x     Document Type: Article

References (51)

1. Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2003 176 99.
2. Look AT. Molecular pathogenesis of MDS. Hematology Am Soc Hematol Educ Program 2005 156 60.
3. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France) : IARC Press 2001.
4. Parker JE, Mufti GJ. The myelodysplastic syndromes: a matter of life or death. Acta Haematol 2004 111 : 78 99.
5. Burzynski SR. Antineoplastons: history of the research (I). Drugs Exp Clin Res 1986 12 (suppl1) : 1 9.
6. Badria F, Mabed M, Khafagy W, Abou-Zeid L. Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett 2000 155 : 67 70.
7. Lin WC, Wu YW, Lai TY, Liau MC. Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain. Am J Chin Med 2001 29 : 91 9.
8. Lin WC, Liao YC, Liau MC, Lii CK, Sheen LY. Inhibitory effect of CDA-II, a urinary preparation, on aflatoxin B(1)-induced oxidative stress and DNA damage in primary cultured rat hepatocytes. Food Chem Toxicol 2006 44 : 546 51.
9. Yao CJ, Lai GM, Chan CF, Yang YY, Liu FC, Chuang SE. Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway. J Altern Complement Med 2005 11 : 903 8.
10. Steube KG, Gignac SM, Hu ZB, Teepe D, Harms D, Kabisch H, et al. In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. Leuk Lymphoma 1997 25 : 345 63.
11. Drexler HG. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. Leuk Res 2000 24 : 109 15.
12. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 2005 12 (Suppl 1) : 942 61.
13. Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol 2002 63 : 689 92.
14. Chandrasekar B, Vemula K, Surabhi RM, Li-Weber M, Owen-Schaub LB, Jensen LE, et al. Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem 2004 279 : 20 221 33.
15. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000 102 : 43 53.
16. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007 35 : 1739 46.
17. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 2005 106 : 3917 25.
18. Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006 8 : 645 54.
19. Lee R, Collins T. Nuclear factor-kappaB and cell survival: IAPs call for support. Circ Res 2001 88 : 262 4.
20. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998 188 : 211 6.
21. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001 20 : 7342 51.
22. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001 21 : 5299 305.
23. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kappaB in development and progression of human cancer. Virchows Arch 2005 446 : 475 82.
24. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998 12 : 806 19.
25. Burkle A. Physiology and pathophysiology of poly(ADP-ribosyl) ation. Bioessays 2001 23 : 795 806.
26. Tong WM, Cortes U, Wang ZQ. Poly (ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 2001 1552 : 27 37.
27. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004 18 : 189 218.
28. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005 17 : 150 7.
29. Nyàkern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006 20 : 230 8.
30. Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005 97 : 26 34.
31. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, et al. Inhibition of Bad phosphorylation either at serine-112 via extracellular signal-regulated protein kinase cascade or at serine-136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000 60 : 5988 94.
32. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999 13 : 2905 27.
33. Kennedy SG, Wagner AJ, Conzen SD, Jordán J, Bellacosa A, Tsichlis PN, et al. The PI3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997 11 : 701 13.
34. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999 21 : 99 102.
35. Béraud C, Henzel WJ, Baeuerle PA. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci USA 1999 96 : 429 34.
36. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006 107 : 1156 65.
37. Sanz C, Richard C, Prosper F, Fernandez-Luna JL. Nuclear factor kappa B is activated in myelodysplastic bone marrow cells. Haematologica 2002 87 : 1005 6.
38. Takada Y, Kobayashi Y, Aggarwal BB. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 2005 280 : 17 203 12.
39. Baldwin AS Jr., Azizkhan JC, Jensen DE, Beg AA, Coodly LR. Induction of NF-kappa B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts. Mol Cell Biol 1991 11 : 4943 51.
40. Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, et al. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J Biol Chem 1999 274 : 25 245 9.
41. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995 81 : 323 30.
42. Armstrong JS. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 2007 151 : 1154 65.
43. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993 74 : 609 19.
44. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003 101 : 2125 31.
45. Dlugosz PJ, Billen LP, Annis MG, Zhu W, Zhang Z, Lin J, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J 2006 25 : 2287 96.
46. Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005 5 : 251 65.
47. Ryningen A, Ersvaer E, Oyan AM, Kalland KH, Vintermyr OK, Gjertsen BT, et al. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML)cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 2006 30 : 1531 40.
48. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006 108 : 630 7.
49. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004 279 : 5405 12.
50. Yamamoto K, Abe S, Nakagawa Y, Suzuki K, Hasegawa M, Inoue M, et al. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res 2004 28 : 1203 11.
51. Benesch M, Platzbecker U, Ward J, Deeg HJ, Leisenring W. Expression of FLIP(Long) and FLIP(Short) in bone marrow mono-nuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 2003 17 : 2460 6.